Home > Resources > Company Profiles > Affymetrix, Incorporated

Affymetrix, Incorporated (AFFX)

Your Name

Your Email Address *
Send a copy to me

Recipient's Email Address *

Separate multiple email addresses (max 20) with commas.

Subject *

Message

0/1500

Email Confirmation

Dr.Stephen P.A. Fodor, Ph.D. , Founder/CEO/Chairman of the Board/Director

www.affymetrix.com

Industry: Technology

OPEN

LAST

PREV CLOSE

CHANGE

VOLUME

Overview

News

People

Financials

Overview

The Company is engaged in the development, manufacture, sale & service of consumables & systems for genetic analysis in the life sciences & clinical healthcare markets and create tools that advances the understanding of the molecular basis of life.

Portfolio Articles

Gene-Sequencing Warrior
Illumina C.E.O. Jay Flatley is moving fast to outmaneuver rivals in a futuristic industry that stands to make billions of dollars off your DNA.
Feb 13 2008
Welcome to the Future
With a little help from Google, secretive Silicon Calley startup 23andMe is betting you’ll want to web-surf your own DNA. But is the science ready?

Oct 15 2007

See more news on this company

News Feeds

Affymetrix licenses genetic analysis technology AP
Oct 01 2008

Portfolio Blogs

When's a Gene Test Not a Gene Test?
Jun 25 2008

Press Releases

South African Core Lab Adopts Affymetrix Technology for Genomic Studies Oct-07-2008, 08:00AM EDT
Wall Street Journal Selects PhyloChip Developed on the Affymetrix Platform as a Top Technology Innovation Oct-03-2008, 08:00AM EDT
Affymetrix and Medical Prognosis Institute Collaborate to Develop Cancer Treatment Products Oct-01-2008, 08:00AM EDT
Affymetrix' GeneTitan(TM) System Delivers Automatic Answers and Sets New Standard in Genomic Analysis Sep-29-2008, 08:00AM EDT
Affymetrix to Distribute Biotique XRAY Software Sep-17-2008, 08:30AM EDT

News From Around the Web

News

Moving forward on genetic testing (The Healthcare Blog)

Oct 10 2008
New Scripps Study on Reaction to Genetic Testing (Fox 6 San Diego (XETV))

Oct 09 2008
Will disease data change patients' habits? (San Diego Union-Tribune)

Oct 09 2008
South African Core Lab Adopts Affymetrix Technology for Genomic Studies (TMCnet.com)

Oct 07 2008
Genetic Engineering & Biotechnology News reports... (First Science)

Oct 04 2008
Affymetrix licenses genetic analysis technology (Boston Globe)

Oct 01 2008
Molecular Diagnostics Take Center Stage (Genetic Engineering News)

Oct 01 2008
Predicting Adverse Drug Reactions (Genetic Engineering News)

Oct 01 2008

Employees

Number of Employees: 1,141

Revenue per Employee: $326,167

Top Executives

Kevin M. King, President

John C. Batty, CFO/Executive VP

Board of Directors

Vernon R. Loucks, Jr., Director

Dr. John D. Diekman, Ph.D., Director

John A. Young, Director

Robert P. Wayman, Director

Barbara A. Caulfield, Esq., Secretary

Dr.Susan D. Desmond-Hellmann, M.D., M.P.H., Director

Dr. Paul A. Berg, Ph.D., Director

Dr. Robert H. Trice, Ph.D., Director

David B. Singer, Director

Financials

Quarterly

Annual

Income Statement	07/2008	04/2008	02/2008	10/2007
Sales	39 Mil.	31.66 Mil.	37.94 Mil.	27.3 Mil.
Gross Operating Profit	47.91 Mil.	137.92 Mil.	69.65 Mil.	67.68 Mil.
Operating Income before D & A (EBITDA)	-1.32 Mil.	94.42 Mil.	16.37 Mil.	17.89 Mil.
Total Income Before Interest Expenses (EBIT)	68 K.	86.58 Mil.	20.99 Mil.	4.16 Mil.
Total Net Income	-3.64 Mil.	46.25 Mil.	12.78 Mil.	2.58 Mil.
Basic EPS, Total	-0.05	0.68	0.19	0.04
Diluted EPS, Total	-0.05	0.58	0.17	0.04

BALANCE STATEMENT	07/2008	04/2008	02/2008	10/2007
Cash and Equivalents	325.73 Mil.	NA	288.64 Mil.	123.74 Mil.
Total Assets	746.59 Mil.	NA	667.11 Mil.	400.23 Mil.
Total Liabilities	78.66 Mil.	NA	84.04 Mil.	79.46 Mil.
Total Capitalization	1.11 Bil.	NA	1.03 Bil.	694.06 Mil.

Cash Flow	07/2008	04/2008	02/2008	10/2007
Net Cash From Continuing Operations	NA	NA	NA	19.36 Mil.
Net Cash From Investing Activities	NA	NA	NA	-27.21 Mil.
Net Cash From Financing Activities	NA	NA	NA	12.23 Mil.
Net Change in Cash & Cash Equivalents	NA	NA	NA	4.67 Mil.

Income Statement	2008	2007	2006	2005
Sales	138.72 Mil.	97.18 Mil.	73.63 Mil.	69.6 Mil.
Gross Operating Profit	232.6 Mil.	258.14 Mil.	293.97 Mil.	276.37 Mil.
Operating Income before D & A (EBITDA)	21.38 Mil.	26.72 Mil.	93.51 Mil.	85.07 Mil.
Total Income Before Interest Expenses (EBIT)	21.5 Mil.	-4.47 Mil.	64.15 Mil.	62.04 Mil.
Total Net Income	12.59 Mil.	-13.7 Mil.	57.52 Mil.	47.61 Mil.
Basic EPS, Total	0.18	-0.2	0.9	0.79
Diluted EPS, Total	0.17	-0.2	0.84	0.74

BALANCE STATEMENT	2008	2007	2006	2005
Cash and Equivalents	288.64 Mil.	119.06 Mil.	100.24 Mil.	42.6 Mil.
Total Assets	667.11 Mil.	383.89 Mil.	452.76 Mil.	322.95 Mil.
Total Liabilities	84.04 Mil.	93.59 Mil.	107.2 Mil.	96.74 Mil.
Total Capitalization	1.03 Bil.	672.96 Mil.	639.84 Mil.	369.19 Mil.

Cash Flow	2008	2007	2006	2005
Net Cash From Continuing Operations	NA	31.26 Mil.	64.61 Mil.	48.93 Mil.
Net Cash From Investing Activities	NA	-22.35 Mil.	-82.3 Mil.	-46.78 Mil.
Net Cash From Financing Activities	NA	9.76 Mil.	74.85 Mil.	-235.08 Mil.
Net Change in Cash & Cash Equivalents	NA	18.83 Mil.	57.64 Mil.	-233.33 Mil.

Affymetrix, Incorporated (AFFX)

Company Information

Overview

Employees

Top Executives

Board of Directors

Financials

Company Profile Change Request